About Anebulo Pharmaceuticals
Anebulo Pharmaceuticals (NASDAQ:ANEB) is a company focused on developing innovative solutions to address acute cannabinoid intoxication and improve public health. Its operations revolve around researching and creating effective treatments for symptoms associated with acute cannabinoid overdose, such as panic, anxiety, and psychosis. Through its various projects, Anebulo Pharmaceuticals aims to lead the way in providing reliable, scientifically backed options for individuals who have inadvertently consumed excessive amounts of cannabinoids. The company's primary objective is to advance its pipeline of treatments to meet the urgent needs of patients and healthcare providers in this emerging area of medical concern, ensuring safety and efficacy are at the forefront of its mission.
Snapshot
Operations
Products and/or services of Anebulo Pharmaceuticals
- Development of ANEB-001, a drug aimed at countering cannabinoid intoxication, addressing a growing concern due to increased use of cannabis.
- Exploration into treatments for other substance-related disorders, leveraging their expertise in cannabinoid receptor systems.
- Research into cannabinoid-based therapeutics for pain management, potentially offering an alternative to opioids.
- Investigation into applications of their technology for treating nausea and vomiting, especially in chemotherapy patients.
- Development of diagnostic tools and technologies for early detection of cannabinoid intoxication.
- Collaboration with academic and research institutions to explore new pathways for the treatment of addiction and substance abuse.
Anebulo Pharmaceuticals executive team
- Dr. Joseph F. Lawler M.D., Ph.D.Founder & Chairman
- Mr. Richard Anthony CunninghamCEO & Director
- Mr. Daniel V. GeorgeActing CFO & Secretary
- Dr. Kenneth C. Cundy Ph.D.Chief Scientific Officer